A randomised trial to investigate whether giving more blood transfusions to people undergoing surgery for hip fracture improves their outcomes

Submission date	Recruitment status Recruiting	[X] Prospectively registered		
28/04/2022		[X] Protocol		
Registration date	Overall study status	Statistical analysis plan		
03/05/2022 Last Edited	Ongoing Condition category	Results		
		☐ Individual participant data		
12/08/2025	Surgery	[X] Record updated in last year		

Plain English summary of protocol

Background and study aims

Hip fracture is the most common serious injury in older people. More than 95% of patients have surgery. This surgery is often high-risk as patients may be frail and have other health problems including heart disease and anaemia (a low blood count). Patients may be in hospital for a long time and need rehabilitation. Up to 35% of surviving patients do not return to their original residence and have a high rate of increased dependency.

Research suggests that 30-40% of these patients have a blood transfusion around the time of operation. However, doctors are uncertain about what level of anaemia transfusions should be given at. Many current guidelines recommend transfusion at a lower level, but there is research which suggests that this level is too low particularly if the patient has a history of heart disease. In these patients, transfusion at a higher level may be better to prevent complications.

Who can participate?

Older (60 years or older) people with a hip fracture and anaemia

What does the study involve?

Participants will be randomly assigned to either receive blood transfusions at a lower blood count, in line with current guidelines, or a higher level, for the duration of their hospital stay, or 30 days, whichever is soonest.

Patients will have their blood count checked before and after any blood transfusions and will have additional blood tests (Troponin) and heart tracings (electrocardiographs, (ECG)) to check their heart.

At 30 days we will measure how often post-operative heart attacks and other complications occur, how long patients stay in hospital and mortality rate. At 30 and 120 days we will measure quality of life (assessed by questionnaire).

The study will last for 4 years but each patient will only be active in the study for 120 days. The study results will help doctors looking after people with hip fracture decide when is the best time to give blood transfusions

What are the possible benefits and risks of participating?

Benefits: There are no clear benefits of taking part in the study. Participants in the liberal arm of the study may receive a few additional transfusions than they would have had if they had not participated in the trial and participants in the restrictive arm may receive slightly fewer transfusions. One arm may be beneficial to participants but we do not know which and are conducting the study to try and find out.

Risks: Blood transfusions are generally very safe but they do carry risks. Transfusion reactions can occur but these are rare and usually mild (for example a fever or rash). Transfusions also have an increased risk of infections or pulmonary oedema although these are very rare.

Where is the study run from? University of Edinburgh (UK)

When is the study starting and how long is it expected to run for? August 2021 to April 2027

Who is funding the study? National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact? Prof. Michael Gillies, michael.gillies@nhslothian.scot.nhs.uk

Contact information

Type(s)

Scientific

Contact name

Prof Michael Gillies

ORCID ID

https://orcid.org/0000-0003-1909-0790

Contact details

The University of Edinburgh
Dept of Anaesthesia, Critical Care and Pain Medicine
Royal Infirmary of Edinburgh
51 Little France Crescent
Edinburgh
United Kingdom
EH16 4SA
+44 131 242 1642
michael.gillies@nhslothian.scot.nhs.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

308830, 299977

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CPMS 52646, IRAS 299977 (Scotland), IRAS 308830 (England and Wales), AC21119

Study information

Scientific Title

The impact of REStrictive versUs Liberal Transfusion strategy on cardiac injury and death in patients undergoing surgery for Hip Fracture (RESULT-Hip)

Acronym

RESULT Hip Version 1

Study objectives

Do patients with hip fracture have better clinical outcomes when a more liberal transfusion practice is used to treatanaemia?

Ethics approval required

Old ethics approval format

Ethics approval(s)

- 1. Approved 17/03/2022, Scotland A Research Ethics Committee (2ndFloor, Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH1 3EG, UK; +44 (0)7814 764 241; manx.neill@nhslothian.scot.nhs. uk), ref: 22/SS/0001
- 2. Approved 18/03/2022, North West- Haydock Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 207 1048032; haydock@rec.hra.nhs.uk), ref: 22/NW/0065

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Blood transfusion for recovery from hip surgery

Interventions

Current interventions as of 03/07/2025:

To answer the study question accurately we will need to recruit 842 patients, they will be split between the two arms of the study. This will allow us to detect a difference in the main

outcome. This figure has been calculated using information from our previous pilot study and allows for some patients to drop out of the study.

The whole project will take 69 months to complete. However, each patient is only actively involved for 120 days post-randomisation.

Previous interventions as of 17/11/2023:

RESULT-Hip is a multicentre randomised trial of the effect of two blood transfusion strategies in patients with hip fractures on cardiac complications. One group of patients will have a restrictive transfusion strategy, which follows published guidelines, and the other a more liberal strategy. This is described more fully below. The study will take place in 30 UK hospitals that look after patients with hip fractures.

When a patient is admitted to the hospital after breaking their hip, almost all go on to have surgery to treat this condition. They will be assessed by the clinical team or research team (where part of the clinical team) in the hospital to see if they meet the age inclusion criteria and do not have any exclusion criteria for the study. Those receiving palliative care (i.e. do not have surgery), who have life-threatening haemorrhage at the time of screening, pre-randomisation acute, or suspected acute, coronary syndrome, objection to receiving RBC transfusion or chronic transfusion-dependent anaemia, will be excluded. This can take place from the time the patient enters the hospital and up to and including 7 days post-surgery.

If the patient meets the criteria they will be approached by a member of the clinical team or research team (where part of the clinical team) to discuss whether they are interested in taking part in the study. If they are, a member of the research team will take consent from the patient to randomise them to the study if they become anaemic (Hb \leq 90 g/L) (considered 'consent in principle' or pre-consent')

If the patient lacks mental capacity, then the research team will approach a family member or personal consultee, or professional consultee (if appropriate) to discuss the patient taking part in the study.

If the patient (or consultee) consents then if the Hb trigger value (Hb \leq 90 g/L) is reached the patient will be randomised to one arm or other of the study. The two arms will have all the same tests done. The difference between the two will be the point at which a blood transfusion is given.

In one arm the transfusion will be given when the level of haemoglobin in the blood is $\leq 90g/L$. This is called the "liberal" transfusion strategy. The aim will be to keep the haemoglobin in the range 90 - 110g/L. In the other arm the transfusion will be given when the level of haemoglobin in the blood is $\leq 75g/L$. This is called the "restrictive" transfusion strategy and is the usual, or standard, level of transfusion in patients undergoing surgery for hip fracture. The aim will be to keep the haemoglobin in the range 75-90 g/L. Participants in both arms of the trial will follow either the restrictive or liberal strategy for the duration of their stay in acute hospital or until 30 days following randomisation whichever is soonest.

We will follow up what happens to all the patients on both arms. The main (primary) outcome (we are interested in studying is about damage to the heart (cardiac injury) and death after this emergency surgery. The rate of occurrence of each of these may be different in the two arms of the study.

To accurately measure the rate of damage to the heart, participants in both arms of the trial will have some additional tests done specifically for the study. They will have blood samples taken to check for levels of a chemical called troponin. Blood samples for troponin testing will be taken when participants are randomised to the trial and twice more between days 1 and 5 following randomisation. Where possible blood samples will be taken at the same time as routine hospital blood samples to minimise inconvenience to the participant. The blood samples will be frozen at the hospital and later transported to Edinburgh for analysis.

Participants will have electrocardiographs (ECG, or heart trace) taken at randomisation and once more during days 2-5 following randomisation. The ECG checks the heart's rhythm and electrical activity. It is a common and painless test carried out by attaching sensors to the participant's chest.

We are also interested in how the participant's quality of life is affected by the intervention, and we will ask them to complete a simple quality of life questionnaire (EQ-5D-5L), which takes just a few minutes to complete, at the time they are randomised to the study.

We will collect data at 30 days and 120 days after randomisation if the participant is still alive. This will allow us to assess whether the blood transfusion affects time in hospital, recovery, and quality of life after this type of surgery. This will be done by asking the participant to complete the EQ-5D-5L questionnaire again which can be done over the telephone. We will also ask the participant to answer a short questionnaire about their health service usage at both 30 and 120 days. The rest of the data that we need for the study is collected from the participant's medical records. After these final questionnaires, at 120 days, we will not require anything else from the participant.

In participants that lack capacity, we will ask the participant's personal consultee to complete the proxy EQ-5D-5L questionnaire at randomisation. We will ask the consultee for permission to contact them at 30 and 120 days (if the participant has not regained capacity) for the completion of the EQ-5D-5L and health resource questionnaires on the participant's behalf.

To answer the study question accurately we will need to recruit 1964 patients, they will be split between the two arms of the study. This will allow us to detect a difference in the main outcome. This figure has been calculated using information from our previous pilot study and allows for some patients to drop out of the study.

The whole project will take 48 months to complete. However, each patient is only actively involved for 120 days post-randomisation.

Process Evaluation

We will include a process evaluation of the internal pilot study consistent with MRC guidance. Our objectives are: to establish the extent to which the intervention is implemented as intended during the internal pilot across different sites; to ascertain how feasible and acceptable the intervention is to clinical staff across different sites; to identify any facilitators and barriers to recruitment.

The methods used to conduct the PE of the internal pilot will be: During Site Initiation Visit - to identify key research staff, collect baseline data on context and establish the acceptability of study protocol. During the internal pilot - all sites in the internal pilot will be invited to participate in individual interviews. Interviews will be conducted remotely by telephone, or by web-based service. Sampling will be used to ensure a range of participants according to grade, profession and role in the research or clinical teams. Interviews will be recorded, transcribed and analysed to identify common themes. The findings of the process evaluation will be reported to the Trial Management and Trial Steering Groups and will feed into decisions about the on-going progress and management of the trial.

Previous interventions:

RESULT-Hip is a multicentre randomised trial of the effect of two blood transfusion strategies in patients with hip fractures on cardiac complications. One group of patients will have a restrictive transfusion strategy, which follows published guidelines, and the other a more liberal strategy. This is described more fully below. The study will take place in 30 UK hospitals that look after patients with hip fractures.

When a patient is admitted to the hospital after breaking their hip, almost all go on to have surgery to treat this condition. They will be assessed by the clinical team or research team (where part of the clinical team) in the hospital to see if they meet the age inclusion criteria and do not have any exclusion criteria for the study. Those receiving palliative care (i.e. do not have surgery), who have life-threatening haemorrhage at the time of screening, pre-randomisation acute coronary syndrome or objection to receiving RBC transfusion will be excluded. This can take place from the time the patient enters the hospital and up to and including 7 days post-surgery.

If the patient meets the criteria they will be approached by a member of the clinical team or research team (where part of the clinical team) to discuss whether they are interested in taking part in the study. If they are, a member of the research team will take consent from the patient to randomise them to the study if they become anaemic (Hb \leq 90 g/L) (considered 'consent in principle' or pre-consent')

If the patient lacks mental capacity, then the research team will approach a family member or personal consultee, or professional consultee (if appropriate) to discuss the patient taking part in the study.

If the patient (or consultee) consents then if the Hb trigger value (Hb \leq 90 g/L) is reached the patient will be randomised to one arm or other of the study. The two arms will have all the same tests done. The difference between the two will be the point at which a blood transfusion is given.

In one arm the transfusion will be given when the level of haemoglobin in the blood is $\leq 90g/L$. This is called the "liberal" transfusion strategy. The aim will be to keep the haemoglobin in the range 90 - 110g/L. In the other arm the transfusion will be given when the level of haemoglobin in the blood is $\leq 75g/L$. This is called the "restrictive" transfusion strategy and is the usual, or standard, level of transfusion in patients undergoing surgery for hip fracture. The aim will be to keep the haemoglobin in the range 75-90 g/L. Participants in both arms of the trial will follow either the restrictive or liberal strategy for the duration of their stay in acute hospital or until 30 days following randomisation whichever is soonest.

We will follow up what happens to all the patients on both arms. The main (primary) outcome (we are interested in studying is about damage to the heart (cardiac injury) and death after this emergency surgery. The rate of occurrence of each of these may be different in the two arms of the study.

To accurately measure the rate of damage to the heart, participants in both arms of the trial will have some additional tests done specifically for the study. They will have blood samples taken to check for levels of a chemical called troponin. Blood samples for troponin testing will be taken when participants are randomised to the trial, on day 1 and once more between days 2 - 5 following randomisation. Where possible blood samples will be taken at the same time as routine hospital blood samples to minimise inconvenience to the participant. The blood samples will be frozen at the hospital and later transported to Edinburgh for analysis.

Participants will have electrocardiographs (ECG, or heart trace) taken at randomisation and once more during days 2-5 following randomisation. The ECG checks the heart's rhythm and electrical activity. It is a common and painless test carried out by attaching sensors to the participant's chest.

We are also interested in how the participant's quality of life is affected by the intervention, and we will ask them to complete a simple quality of life questionnaire (EQ-5D-5L), which takes just a few minutes to complete, at the time they are randomised to the study.

We will collect data at 30 days and 120 days after randomisation if the participant is still alive. This will allow us to assess whether the blood transfusion affects time in hospital, recovery, and quality of life after this type of surgery. This will be done by asking the participant to complete the EQ-5D-5L questionnaire again which can be done over the telephone. We will also ask the participant to answer a short questionnaire about their health service usage at both 30 and 120 days. The rest of the data that we need for the study is collected from the participant's medical records. After these final questionnaires, at 120 days, we will not require anything else from the participant.

In participants that lack capacity, we will ask the participant's personal consultee to complete the proxy EQ-5D-5L questionnaire at randomisation. We will ask the consultee for permission to contact them at 30 and 120 days (if the participant has not regained capacity) for the completion of the EQ-5D-5L and health resource questionnaires on the participant's behalf.

To answer the study question accurately we will need to recruit 1964 patients, they will be split between the two arms of the study. This will allow us to detect a difference in the main outcome. This figure has been calculated using information from our previous pilot study and allows for some patients to drop out of the study.

The whole project will take 48 months to complete. However, each patient is only actively involved for 120 days post-randomisation.

Process Evaluation

We will include a process evaluation of the internal pilot study consistent with MRC guidance. Our objectives are: to establish the extent to which the intervention is implemented as intended during the internal pilot across different sites; to ascertain how feasible and acceptable the intervention is to clinical staff across different sites; to identify any facilitators and barriers to recruitment.

The methods used to conduct the PE of the internal pilot will be: During Site Initiation Visit - to identify key research staff, collect baseline data on context and establish the acceptability of study protocol. During the internal pilot - all sites in the internal pilot will be invited to participate in individual interviews. Interviews will be conducted remotely by telephone, or by web-based service. Sampling will be used to ensure a range of participants according to grade, profession and role in the research or clinical teams. Interviews will be recorded, transcribed and analysed to identify common themes. The findings of the process evaluation will be reported to the Trial Management and Trial Steering Groups and will feed into decisions about the on-going progress and management of the trial.

Intervention Type

Other

Primary outcome(s)

Current primary outcome measure as of 03/07/2025:

Death or major cardiac adverse events (MACE) or new MINS measured using patient records up to 30 days

Previous primary outcome measure:

Death or major cardiac adverse events (MACE) measured using patient records up to 30 days

Key secondary outcome(s))

Measured using patient records at 30 days:

- 1. All cause mortality
- 2. Myocardial injury post randomisation (troponin >99th centile (URL) AND a 20% change from baseline)
- 3. Individual MACE components
- 4. Complications (including AKI, delirium, stroke, pulmonary embolus)
- 5. Proportion of participants transfused
- 6. Discharge destination
- 7. Acute hospital length of stay
- 8. EQ-5D-5L9. Health services resource utilisation (from questionnaires)

Additional secondary outcome measures

Measured using patient records at 120 days:

- 1. All cause mortality
- 2. Discharge destination
- 3. Acute hospital length of stay
- 4. unplanned hospital readmissions
- 5. Mobility
- 6. Residential status
- 7. EQ-5D-5L9., Health services resource utilisation (from questionnaire)

Completion date

30/04/2027

Eligibility

Key inclusion criteria

Current participant inclusion criteria as of 17/11/2023:

- 1. Adults aged 60 years or over
- 2. Admission to acute unit for operative management of hip fracture

For Randomisation:

3. Presence of anaemia (Haemoglobin equal to or less than 90 g/L) at any point between the date of admission to hospital up to and including seven days after surgery

Previous participant inclusion criteria:

- 1. Adults aged 60 years or over
- 2. Admission to hospital for operative management of hip fracture

For Randomisation:

3. Presence of anaemia (Haemoglobin equal to or less than 90 g/L) at any point between the date of admission to hospital up to and including seven days after surgery

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

60 years

Sex

All

Key exclusion criteria

Current exclusion criteria as of 03/07/2025:

- 1. Objection to RBC transfusion
- 2. Unable to obtain consent (from patient or in accordance with appropriate mental capacity legislation for site)
- 3. Patients for non-operative management or not expected to survive 48 hours
- 4. Patients with a new or suspected acute coronary syndrome meeting 4th Universal Definition during current admission
- 5. Rapid or uncontrolled blood loss resulting in haemodynamic instability
- 6. Chronic anaemia requiring repeated transfusion (eg Myelodysplasia or bone marrow failure syndromes)

Previous participant exclusion criteria as of 17/11/2023:

- 1. Objection to RBC transfusion
- 2. Unable to obtain consent (from patient or in accordance with appropriate mental capacity legislation for site)
- 3. Patients for non-operative management or not expected to survive 48 hours
- 4. Patients with a new or suspected acute coronary syndrome meeting 4th Universal Definition during current admission
- 5. Rapid or uncontrolled blood loss resulting in haemodynamic instability
- 6. Transfusion dependent/chronic anaemias (eg Myelodysplasia or bone marrow failure syndromes)

Previous participant exclusion criteria:

- 1. Objection to RBC transfusion
- 2. Unable to obtain consent (from patient or in accordance with appropriate mental capacity legislation for site)
- 3. Patients for non-operative management or not expected to survive 48 hours
- 4. Patients with a new acute coronary syndrome meeting 4th Universal Definition during current admission
- 5. Rapid or uncontrolled blood loss resulting in haemodynamic instability

Date of first enrolment

01/06/2022

Date of final enrolment

30/04/2026

Locations

Countries of recruitment

United Kingdom

England

Scotland

Study participating centre
Royal Infirmary of Edinburgh at Little France
51 Little France Crescent

Old Dalkeith Road Edinburgh Lothian United Kingdom EH16 4SA

Study participating centre John Radcliffe Hospital

Headley Way Headington Oxford United Kingdom OX3 9DU

Study participating centre Glasgow Royal Infirmary

84 Castle Street Glasgow United Kingdom G4 0SF

Study participating centre Wishaw General Hospital

50 Netherton Street Wishaw United Kingdom ML2 0DP

Study participating centre Borders General Hospital

Huntlyburn Terrace Melrose United Kingdom TD6 9BS

Study participating centre Rotherham General Hospital

Moorgate Road Rotherham United Kingdom S60 2UD

Study participating centre Southmead Hospital

Southmead Road Westbury-on-trym Bristol United Kingdom BS10 5NB

Study participating centre Norfolk and Norwich University Hospital

Colney Lane Colney Norwich United Kingdom NR4 7UY

Study participating centre Leicester Royal Infirmary

Infirmary Square Leicester United Kingdom LE1 5WW

Study participating centre Southampton General Hospital

Tremona Road Southampton United Kingdom SO16 6YD

Study participating centre University Hospital of North Tees

Hardwick Road Stockton-on-tees United Kingdom TS19 8PE

Study participating centre Dumfries and Galloway Royal Infirmary

Bankend Road
Dumfries
Dumfries and Galloway
United Kingdom
DG1 4AP

Study participating centre Victoria Hospital

Hayfield Road Kirkcaldy United Kingdom KY25AH

Study participating centre The James Cook University Hospital

Marton Road Middlesbrough United Kingdom TS4 3BW

Study participating centre Horton General Hospital

81a Oxford Road Banbury United Kingdom OX16 9AL

Study participating centre Hereford County Hospital

Stonebow Road Hereford United Kingdom HR1 2BN

Study participating centre Royal Albert Edward Infirmary

Wigan Lane Wigan United Kingdom WN1 2NN

Study participating centre Ipswich Hospital Heath Road

Ipswich United Kingdom IP4 5PD

Study participating centre East Surrey Hospital

Canada Avenue Redhill United Kingdom RH1 5RH

Study participating centre Worcestershire Royal Hospital

Charles Hastings Way Worcester United Kingdom WR5 1DD

Study participating centre Aberdeen Royal Infirmary

Foresterhill Road Aberdeen United Kingdom AB25 2ZN

Study participating centre North Devon District Hospital

Raleigh Park Barnstaple United Kingdom EX31 4JB

Study participating centre Darlington Memorial Hospital

Hollyhurst Road Darlington United Kingdom DL3 6HX

Study participating centre Royal Devon and Exeter Hospital

Royal Devon & Exeter Hospital Barrack Road Exeter United Kingdom EX2 5DW

Study participating centre University Hospital of North Durham Cdc

University Hospital of North Durham North Road Durham United Kingdom DH1 5TW

Study participating centre Southport and Formby District General Hospital

Town Lane Southport United Kingdom PR8 6PN

Study participating centre Stoke Mandeville Hospital

Mandeville Road Aylesbury United Kingdom HP21 8AL

Study participating centre Royal Victoria Hospital

Queen Victoria Road Newcastle upon Tyne United Kingdom NE1 4LP

Study participating centre Croydon University Hospital

London Road Croydon United Kingdom CR7 7YE

Study participating centre
The Princess Alexandra Hospital NHS Trust
Hamstel Road
Harlow
United Kingdom
CM20 1QX

Study participating centre
Hull University Teaching Hospitals NHS Trust
Hull Royal Infirmary
Anlaby Road
Hull
United Kingdom
HU3 2JZ

Sponsor information

Organisation

University of Edinburgh and NHS Lothian Health Board

Funder(s)

Funder type

Government

Funder Name

NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC)

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type HRA research summary HRA research summary	Details	Date created	Date added 28/06/2023 26/07/2023		Patient-facing? No No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025		Yes
<u>Protocol file</u>	version 3	15/09/2022	17/11/2023	No	No
Protocol file	version 4	03/05/2023	25/07/2024	No	No
Protocol file	version 5	26/06/2024	03/07/2025	No	No
Protocol file	version 6	31/01/2025	12/08/2025	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes